Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Merck & Co. discontinues development of MK-6913 for hot flashes

Sep. 9, 2010

New glucagon receptor antagonists claimed by Merck & Co.

Sep. 9, 2010

AstraZeneca identifies new histamine H3 receptor antagonists

Sep. 8, 2010

Banyu Pharmaceutical discloses new DGAT-1 inhibitors

Sep. 8, 2010

NC-2500 is selected for clinical development in gout-related hyperuricemia

Sep. 7, 2010

Banyu Pharmaceutical discloses novel inhibitors of MGAT2

Sep. 7, 2010

GSK responds to article on rosiglitazone

Sep. 7, 2010

Levitra orodispersible tablet is approved in Europe for erectile dysfunction

Sep. 6, 2010

MSD and Faes Farma to market sitagliptin and sitagliptin/metformin in Spain

Sep. 6, 2010

Eisai launches Glufast in China for type 2 diabetes

Sep. 6, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 1, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...
Ascending BCI systems deepen national security, ethical concerns
BioWorld
Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...